Literature DB >> 24713153

Impact of transcatheter closure of patent foramen ovale in the evolution of migraine and role of residual shunt.

Luigi Biasco1, Vincenzo Infantino2, Fulvio Orzan2, Silvia Vicentini2, Chiara Rovera2, Giada Longo2, Alessandra Chinaglia3, Riccardo Belli3, Gianni Allais4, Fiorenzo Gaita2.   

Abstract

OBJECTIVES: To retrospectively evaluate the impact on daily activities of transcatheter closure of patent foramen ovale (PFO) versus medical therapy in patients with migraine and to analyze the role of the residual shunt after PFO closure.
BACKGROUND: While non-controlled observational studies reported an improvement of migraine after PFO closure, a randomized trial has shown no benefit of such an intervention. The role of residual shunt after PFO closure is also poorly known.
METHODS: Out of 217 patients with migraine and echocardiographic evidence of PFO, 89 were managed with percutaneous PFO closure (Group A) while 128 were medically treated (Group B). All MIDAS questionnaires were obtained at the first evaluation and repeated at least 6 months after the index evaluation or after the PFO closure. All the patients were also asked to give a subjective estimate of their migraine status. A postprocedural transcranial Doppler study was available in 70 patients in Group A.
RESULTS: The mean basal MIDAS score did not differ between the two groups (p = 0.859). After a mean follow-up (FU) of 1399 ± 982 days the MIDAS score decreased significantly in both groups (Group A baseline vs FU, p < 0.001; Group B baseline vs FU, p < 0.001), but no differences were observed between groups (p = 0.204). However a significantly higher number of Group A patients reported a perceived clinical benefit or the disappearance of migraine compared to Group B (p < 0.001). Patients with moderate or severe residual right to left shunt were no more likely to have an higher MIDAS score or to complain of migraine than those with mild or no shunt.
CONCLUSIONS: Although the overall evolution of migraine is not significantly different, the abolition of migraine occurs in a larger proportion after PFO closure.
Copyright © 2014. Published by Elsevier Ltd.

Entities:  

Keywords:  Migraine; Patent foramen ovale; Transcatheter closure

Mesh:

Year:  2014        PMID: 24713153     DOI: 10.1016/j.jjcc.2014.02.023

Source DB:  PubMed          Journal:  J Cardiol        ISSN: 0914-5087            Impact factor:   3.159


  6 in total

Review 1.  PFO and Migraine: Is There a Role for Closure?

Authors:  Melissa Rayhill; Rebecca Burch
Journal:  Curr Neurol Neurosci Rep       Date:  2017-03       Impact factor: 5.081

Review 2.  Migraine and percutaneous patent foramen ovale closure: a systematic review and meta-analysis.

Authors:  Yu-Jie Shi; Jun Lv; Xing-Ting Han; Guo-Gang Luo
Journal:  BMC Cardiovasc Disord       Date:  2017-07-26       Impact factor: 2.298

3.  The Efficacy of Percutaneous Patent Foramen Ovale Closure on Migraine: a Meta-Analysis of Randomized Controlled Trials and Observational Studies.

Authors:  Quan-Quan Zhang; Jia-Jie Lu; Man-Yun Yan; Xiao-Wei Hu; Yi-Ren Qin; Da-Peng Wang; Jian-Hua Jiang; Qi Fang; Hong-Ru Zhao
Journal:  Biomed Res Int       Date:  2021-03-04       Impact factor: 3.411

4.  Effectiveness and Safety of Transcatheter Patent Foramen Ovale Closure for Migraine (EASTFORM) Trial.

Authors:  Ying-Qi Xing; Yu-Zhu Guo; Yong-Sheng Gao; Zhen-Ni Guo; Peng-Peng Niu; Yi Yang
Journal:  Sci Rep       Date:  2016-12-14       Impact factor: 4.379

Review 5.  Migraine and risk of stroke.

Authors:  Lise R Øie; Tobias Kurth; Sasha Gulati; David W Dodick
Journal:  J Neurol Neurosurg Psychiatry       Date:  2020-03-26       Impact factor: 10.154

Review 6.  Association of migraine with patent foramen ovale closure: A systematic review and meta-analysis.

Authors:  Yan-Li Wang; Fang-Ze Wang; Yuan Zhang; Jiwei Jiang; Ziyan Jia; Xiangrong Liu; Jian Wang; Jun Xu
Journal:  Int J Cardiol Heart Vasc       Date:  2022-03-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.